Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials

Rory Collins(University of Oxford), Jordan Fulcher, Jonathan Emberson(University of Oxford), Christoph Wanner(Universitätsklinikum Würzburg), Patrick B. Mark(Queen Elizabeth University Hospital), Lisa Blackwell(University of Oxford), Marit D. Solbu, Alan G. Jardine(Western Infirmary), Christina Reith(University of Oxford), Borislava Mihaylova(Queen Mary University of London), William G. Herrington(Oxford Health NHS Foundation Trust), Martin Landray(Gentofte Hospital), Hallvard Holdaas(Oslo University Hospital), Richard Haynes, Bengt Fellström(Uppsala University Hospital), Anthony Keech(Heidelberg University), John Simes(The University of Sydney)
The Lancet Diabetes & Endocrinology
July 30, 2016
10.1016/s2213-8587(16)30156-5
Cited by 338

Related Papers

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
|New England Journal of Medicine|2017|6k
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
|The Lancet|2003|3.8k
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
|The Lancet|2015|3.7k
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
|New England Journal of Medicine|2016|3.6k
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial
|The Lancet|2005|2.9k